BioSense
BioSense developed the first working non-contact ECG solution, featuring thin, flexible sensors that detect ECG signals through multiple fabric layers without skin contact and integrate with hospital monitors for various patient monitoring applications.
BioSense Services
BioSense specializes in the development of non-contact ECG solutions, catering to various medical settings including NICU, Delivery, Burn Units, and adult monitoring. Their innovative technology allows for remote and daily patient monitoring without the need for direct skin contact, enhancing patient comfort and facilitating continuous health tracking. Additionally, BioSense integrates its non-contact ECG solutions with existing hospital monitoring systems for comprehensive patient care.
BioSense Products
BioSense offers a pioneering non-contact ECG monitoring device that utilizes thin, flexible sensors. These sensors are capable of detecting ECG signals through multiple layers of fabric, thus eliminating the need for direct skin contact. The product includes a signal processing unit that can be embedded into a mattress for rapid ECG acquisition, with results available in about 10 seconds. The device has demonstrated 95-99% correlation with FDA cleared devices across multiple ECG biomarkers, ensuring its reliability and accuracy in various clinical environments.
BioSense Technology
BioSense's technology comprises advanced, thin, and flexible sensors finely tuned to capture ECG signals without interfering with other electrical devices in a medical setting. The sensors, when integrated into a signal processing unit, enable the acquisition of medical-grade ECG signals through multiple layers of clothing or fabric. This innovation supports hospital integration, allowing medical practitioners to monitor patients effectively using existing hospital monitors. The device has proven efficacy in quickly detecting ECG signals, with a proven correlation to standard medical devices.
BioSense Research and Development
BioSense is engaged in rigorous research and development to advance its non-contact ECG solutions. The company has conducted extensive correlation analysis using ECG simulators and human trials, demonstrating a 95-99% correlation with FDA cleared devices across multiple ECG biomarkers. BioSense's research efforts are currently progressing toward clinical trials in hospitals, aiming to validate the technology further and broaden its clinical applications. With capabilities to monitor over 480 biomarkers in the EKG signal, BioSense's technology holds potential for diagnosing hundreds of medical conditions.